{"entity":{"type":"insider","cik":"0001612096","url":"/insider/0001612096","json_url":"/insider/0001612096.json","name":"Ciechanover Isaac E.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":327,"n_filings":94,"first":"2015-04-24","last":"2019-05-31","span_basis":"filed_date"},"name_variants":[{"name":"Ciechanover Isaac E.","source":"filing","n_filings":94,"first_seen":"2015-04-24","last_seen":"2019-05-31"}],"transactions":[{"id":8391642,"accession":"0001209191-19-033638","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-19-033638","line_url":"/filing/0001209191-19-033638","is_derivative":false,"issuer_cik":"0001604464","issuer_name":"Atara Biotherapeutics, Inc.","issuer_ticker":"ATRA","issuer_name_source":null,"issuer_url":"/issuer/0001604464","owner_cik":"0001612096","owner_name":"Ciechanover Isaac E.","owner_display_name":"Ciechanover Isaac E.","owner_url":"/insider/0001612096","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2925.0,"shares_display":"2,925","price_per_share":23.222564102564103,"price_display":"23.22","price_state":"stated","total_value":67926.0,"total_display":"67,926.00","total_whole":"67,926","shares_owned_after":290687.0,"shares_owned_after_display":"290,687","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-30","filed_date":"2019-05-31","scope":"insider","n_lines":2},{"id":8391636,"accession":"0001209191-19-033638","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-19-033638","line_url":"/filing/0001209191-19-033638","is_derivative":false,"issuer_cik":"0001604464","issuer_name":"Atara Biotherapeutics, Inc.","issuer_ticker":"ATRA","issuer_name_source":null,"issuer_url":"/issuer/0001604464","owner_cik":"0001612096","owner_name":"Ciechanover Isaac E.","owner_display_name":"Ciechanover Isaac E.","owner_url":"/insider/0001612096","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2925.0,"shares_display":"2,925","price_per_share":22.96153846153846,"price_display":"22.96","price_state":"stated","total_value":67162.5,"total_display":"67,162.50","total_whole":"67,163","shares_owned_after":294337.0,"shares_owned_after_display":"294,337","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-29","filed_date":"2019-05-31","scope":"insider","n_lines":2},{"id":8238504,"accession":"0001209191-19-030024","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-19-030024","line_url":"/filing/0001209191-19-030024#line-3","is_derivative":false,"issuer_cik":"0001604464","issuer_name":"Atara Biotherapeutics, Inc.","issuer_ticker":"ATRA","issuer_name_source":null,"issuer_url":"/issuer/0001604464","owner_cik":"0001612096","owner_name":"Ciechanover Isaac E.","owner_display_name":"Ciechanover Isaac E.","owner_url":"/insider/0001612096","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3900.0,"shares_display":"3,900","price_per_share":24.92,"price_display":"24.92","price_state":"stated","total_value":97188.0,"total_display":"97,188.00","total_whole":"97,188","shares_owned_after":296537.0,"shares_owned_after_display":"296,537","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-14","filed_date":"2019-05-15","scope":"insider"},{"id":8238500,"accession":"0001209191-19-030024","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-19-030024","line_url":"/filing/0001209191-19-030024","is_derivative":false,"issuer_cik":"0001604464","issuer_name":"Atara Biotherapeutics, Inc.","issuer_ticker":"ATRA","issuer_name_source":null,"issuer_url":"/issuer/0001604464","owner_cik":"0001612096","owner_name":"Ciechanover Isaac E.","owner_display_name":"Ciechanover Isaac E.","owner_url":"/insider/0001612096","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3900.0,"shares_display":"3,900","price_per_share":24.303846153846155,"price_display":"24.30","price_state":"stated","total_value":94785.0,"total_display":"94,785.00","total_whole":"94,785","shares_owned_after":300837.0,"shares_owned_after_display":"300,837","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-13","filed_date":"2019-05-15","scope":"insider","n_lines":2},{"id":8316201,"accession":"0001209191-19-026446","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-19-026446","line_url":"/filing/0001209191-19-026446#line-3","is_derivative":false,"issuer_cik":"0001604464","issuer_name":"Atara Biotherapeutics, Inc.","issuer_ticker":"ATRA","issuer_name_source":null,"issuer_url":"/issuer/0001604464","owner_cik":"0001612096","owner_name":"Ciechanover Isaac E.","owner_display_name":"Ciechanover Isaac E.","owner_url":"/insider/0001612096","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3900.0,"shares_display":"3,900","price_per_share":33.47,"price_display":"33.47","price_state":"stated","total_value":130533.0,"total_display":"130,533.00","total_whole":"130,533","shares_owned_after":304337.0,"shares_owned_after_display":"304,337","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-04-26","filed_date":"2019-04-29","scope":"insider"},{"id":8316194,"accession":"0001209191-19-026446","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-19-026446","line_url":"/filing/0001209191-19-026446","is_derivative":false,"issuer_cik":"0001604464","issuer_name":"Atara Biotherapeutics, Inc.","issuer_ticker":"ATRA","issuer_name_source":null,"issuer_url":"/issuer/0001604464","owner_cik":"0001612096","owner_name":"Ciechanover Isaac E.","owner_display_name":"Ciechanover Isaac E.","owner_url":"/insider/0001612096","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3900.0,"shares_display":"3,900","price_per_share":33.60230769230769,"price_display":"33.60","price_state":"stated","total_value":131049.0,"total_display":"131,049.00","total_whole":"131,049","shares_owned_after":308537.0,"shares_owned_after_display":"308,537","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-04-25","filed_date":"2019-04-29","scope":"insider","n_lines":2},{"id":8675394,"accession":"0001209191-19-024482","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-19-024482","line_url":"/filing/0001209191-19-024482#line-2","is_derivative":false,"issuer_cik":"0001604464","issuer_name":"Atara Biotherapeutics, Inc.","issuer_ticker":"ATRA","issuer_name_source":null,"issuer_url":"/issuer/0001604464","owner_cik":"0001612096","owner_name":"Ciechanover Isaac E.","owner_display_name":"Ciechanover Isaac E.","owner_url":"/insider/0001612096","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3900.0,"shares_display":"3,900","price_per_share":36.27,"price_display":"36.27","price_state":"stated","total_value":141453.0,"total_display":"141,453.00","total_whole":"141,453","shares_owned_after":312137.0,"shares_owned_after_display":"312,137","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-04-11","filed_date":"2019-04-12","scope":"insider"},{"id":8675388,"accession":"0001209191-19-024482","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-19-024482","line_url":"/filing/0001209191-19-024482#line-1","is_derivative":false,"issuer_cik":"0001604464","issuer_name":"Atara Biotherapeutics, Inc.","issuer_ticker":"ATRA","issuer_name_source":null,"issuer_url":"/issuer/0001604464","owner_cik":"0001612096","owner_name":"Ciechanover Isaac E.","owner_display_name":"Ciechanover Isaac E.","owner_url":"/insider/0001612096","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3900.0,"shares_display":"3,900","price_per_share":37.04,"price_display":"37.04","price_state":"stated","total_value":144456.0,"total_display":"144,456.00","total_whole":"144,456","shares_owned_after":316037.0,"shares_owned_after_display":"316,037","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-04-10","filed_date":"2019-04-12","scope":"insider"},{"id":7837568,"accession":"0001209191-19-021972","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-19-021972","line_url":"/filing/0001209191-19-021972","is_derivative":false,"issuer_cik":"0001604464","issuer_name":"Atara Biotherapeutics, Inc.","issuer_ticker":"ATRA","issuer_name_source":null,"issuer_url":"/issuer/0001604464","owner_cik":"0001612096","owner_name":"Ciechanover Isaac E.","owner_display_name":"Ciechanover Isaac E.","owner_url":"/insider/0001612096","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3900.0,"shares_display":"3,900","price_per_share":39.90692307692308,"price_display":"39.91","price_state":"stated","total_value":155637.0,"total_display":"155,637.00","total_whole":"155,637","shares_owned_after":320137.0,"shares_owned_after_display":"320,137","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-03-29","filed_date":"2019-04-01","scope":"insider","n_lines":2},{"id":7837563,"accession":"0001209191-19-021972","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-19-021972","line_url":"/filing/0001209191-19-021972","is_derivative":false,"issuer_cik":"0001604464","issuer_name":"Atara Biotherapeutics, Inc.","issuer_ticker":"ATRA","issuer_name_source":null,"issuer_url":"/issuer/0001604464","owner_cik":"0001612096","owner_name":"Ciechanover Isaac E.","owner_display_name":"Ciechanover Isaac E.","owner_url":"/insider/0001612096","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3900.0,"shares_display":"3,900","price_per_share":37.412564102564104,"price_display":"37.41","price_state":"stated","total_value":145909.0,"total_display":"145,909.00","total_whole":"145,909","shares_owned_after":325737.0,"shares_owned_after_display":"325,737","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-03-28","filed_date":"2019-04-01","scope":"insider","n_lines":3},{"id":8513183,"accession":"0001209191-19-019979","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-19-019979","line_url":"/filing/0001209191-19-019979#line-3","is_derivative":false,"issuer_cik":"0001604464","issuer_name":"Atara Biotherapeutics, Inc.","issuer_ticker":"ATRA","issuer_name_source":null,"issuer_url":"/issuer/0001604464","owner_cik":"0001612096","owner_name":"Ciechanover Isaac E.","owner_display_name":"Ciechanover Isaac E.","owner_url":"/insider/0001612096","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3900.0,"shares_display":"3,900","price_per_share":38.73,"price_display":"38.73","price_state":"stated","total_value":151047.0,"total_display":"151,047.00","total_whole":"151,047","shares_owned_after":327737.0,"shares_owned_after_display":"327,737","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-03-15","filed_date":"2019-03-18","scope":"insider"},{"id":8513180,"accession":"0001209191-19-019979","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-19-019979","line_url":"/filing/0001209191-19-019979","is_derivative":false,"issuer_cik":"0001604464","issuer_name":"Atara Biotherapeutics, Inc.","issuer_ticker":"ATRA","issuer_name_source":null,"issuer_url":"/issuer/0001604464","owner_cik":"0001612096","owner_name":"Ciechanover Isaac E.","owner_display_name":"Ciechanover Isaac E.","owner_url":"/insider/0001612096","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3900.0,"shares_display":"3,900","price_per_share":40.23230769230769,"price_display":"40.23","price_state":"stated","total_value":156906.0,"total_display":"156,906.00","total_whole":"156,906","shares_owned_after":331637.0,"shares_owned_after_display":"331,637","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-03-14","filed_date":"2019-03-18","scope":"insider","n_lines":2},{"id":7945853,"accession":"0001209191-19-014944","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-19-014944","line_url":"/filing/0001209191-19-014944#line-3","is_derivative":false,"issuer_cik":"0001604464","issuer_name":"Atara Biotherapeutics, Inc.","issuer_ticker":"ATRA","issuer_name_source":null,"issuer_url":"/issuer/0001604464","owner_cik":"0001612096","owner_name":"Ciechanover Isaac E.","owner_display_name":"Ciechanover Isaac E.","owner_url":"/insider/0001612096","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3900.0,"shares_display":"3,900","price_per_share":36.13,"price_display":"36.13","price_state":"stated","total_value":140907.0,"total_display":"140,907.00","total_whole":"140,907","shares_owned_after":335537.0,"shares_owned_after_display":"335,537","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-02-28","filed_date":"2019-03-01","scope":"insider"},{"id":7945850,"accession":"0001209191-19-014944","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-19-014944","line_url":"/filing/0001209191-19-014944","is_derivative":false,"issuer_cik":"0001604464","issuer_name":"Atara Biotherapeutics, Inc.","issuer_ticker":"ATRA","issuer_name_source":null,"issuer_url":"/issuer/0001604464","owner_cik":"0001612096","owner_name":"Ciechanover Isaac E.","owner_display_name":"Ciechanover Isaac E.","owner_url":"/insider/0001612096","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3900.0,"shares_display":"3,900","price_per_share":36.149743589743586,"price_display":"36.15","price_state":"stated","total_value":140984.0,"total_display":"140,984.00","total_whole":"140,984","shares_owned_after":339437.0,"shares_owned_after_display":"339,437","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-02-27","filed_date":"2019-03-01","scope":"insider","n_lines":2},{"id":7866092,"accession":"0001209191-19-009508","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-19-009508","line_url":"/filing/0001209191-19-009508#line-3","is_derivative":false,"issuer_cik":"0001604464","issuer_name":"Atara Biotherapeutics, Inc.","issuer_ticker":"ATRA","issuer_name_source":null,"issuer_url":"/issuer/0001604464","owner_cik":"0001612096","owner_name":"Ciechanover Isaac E.","owner_display_name":"Ciechanover Isaac E.","owner_url":"/insider/0001612096","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3900.0,"shares_display":"3,900","price_per_share":39.01,"price_display":"39.01","price_state":"stated","total_value":152139.0,"total_display":"152,139.00","total_whole":"152,139","shares_owned_after":342138.0,"shares_owned_after_display":"342,138","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-02-12","filed_date":"2019-02-12","scope":"insider"},{"id":7866090,"accession":"0001209191-19-009508","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-19-009508","line_url":"/filing/0001209191-19-009508#line-2","is_derivative":false,"issuer_cik":"0001604464","issuer_name":"Atara Biotherapeutics, Inc.","issuer_ticker":"ATRA","issuer_name_source":null,"issuer_url":"/issuer/0001604464","owner_cik":"0001612096","owner_name":"Ciechanover Isaac E.","owner_display_name":"Ciechanover Isaac E.","owner_url":"/insider/0001612096","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3900.0,"shares_display":"3,900","price_per_share":38.52,"price_display":"38.52","price_state":"stated","total_value":150228.0,"total_display":"150,228.00","total_whole":"150,228","shares_owned_after":346038.0,"shares_owned_after_display":"346,038","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-02-11","filed_date":"2019-02-12","scope":"insider"},{"id":8450419,"accession":"0001209191-19-005448","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-19-005448","line_url":"/filing/0001209191-19-005448","is_derivative":false,"issuer_cik":"0001604464","issuer_name":"Atara Biotherapeutics, Inc.","issuer_ticker":"ATRA","issuer_name_source":null,"issuer_url":"/issuer/0001604464","owner_cik":"0001612096","owner_name":"Ciechanover Isaac E.","owner_display_name":"Ciechanover Isaac E.","owner_url":"/insider/0001612096","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3900.0,"shares_display":"3,900","price_per_share":35.07261538461538,"price_display":"35.07","price_state":"stated","total_value":136783.2,"total_display":"136,783.20","total_whole":"136,783","shares_owned_after":296882.0,"shares_owned_after_display":"296,882","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-01-24","filed_date":"2019-01-25","scope":"insider","n_lines":2},{"id":8450414,"accession":"0001209191-19-005448","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-19-005448","line_url":"/filing/0001209191-19-005448","is_derivative":false,"issuer_cik":"0001604464","issuer_name":"Atara Biotherapeutics, Inc.","issuer_ticker":"ATRA","issuer_name_source":null,"issuer_url":"/issuer/0001604464","owner_cik":"0001612096","owner_name":"Ciechanover Isaac E.","owner_display_name":"Ciechanover Isaac E.","owner_url":"/insider/0001612096","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3900.0,"shares_display":"3,900","price_per_share":35.03846153846154,"price_display":"35.04","price_state":"stated","total_value":136650.0,"total_display":"136,650.00","total_whole":"136,650","shares_owned_after":301252.0,"shares_owned_after_display":"301,252","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-01-23","filed_date":"2019-01-25","scope":"insider","n_lines":3},{"id":8525954,"accession":"0001209191-19-003315","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-19-003315","line_url":"/filing/0001209191-19-003315","is_derivative":false,"issuer_cik":"0001604464","issuer_name":"Atara Biotherapeutics, Inc.","issuer_ticker":"ATRA","issuer_name_source":null,"issuer_url":"/issuer/0001604464","owner_cik":"0001612096","owner_name":"Ciechanover Isaac E.","owner_display_name":"Ciechanover Isaac E.","owner_url":"/insider/0001612096","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3900.0,"shares_display":"3,900","price_per_share":34.25153846153846,"price_display":"34.25","price_state":"stated","total_value":133581.0,"total_display":"133,581.00","total_whole":"133,581","shares_owned_after":4078.0,"shares_owned_after_display":"4,078","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-01-10","filed_date":"2019-01-10","scope":"insider","n_lines":2},{"id":8525946,"accession":"0001209191-19-003315","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-19-003315","line_url":"/filing/0001209191-19-003315","is_derivative":false,"issuer_cik":"0001604464","issuer_name":"Atara Biotherapeutics, Inc.","issuer_ticker":"ATRA","issuer_name_source":null,"issuer_url":"/issuer/0001604464","owner_cik":"0001612096","owner_name":"Ciechanover Isaac E.","owner_display_name":"Ciechanover Isaac E.","owner_url":"/insider/0001612096","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3900.0,"shares_display":"3,900","price_per_share":34.843333333333334,"price_display":"34.84","price_state":"stated","total_value":135889.0,"total_display":"135,889.00","total_whole":"135,889","shares_owned_after":7978.0,"shares_owned_after_display":"7,978","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-01-09","filed_date":"2019-01-10","scope":"insider","n_lines":2},{"id":6002022,"accession":"0001209191-18-064352","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-18-064352","line_url":"/filing/0001209191-18-064352","is_derivative":false,"issuer_cik":"0001604464","issuer_name":"Atara Biotherapeutics, Inc.","issuer_ticker":"ATRA","issuer_name_source":null,"issuer_url":"/issuer/0001604464","owner_cik":"0001612096","owner_name":"Ciechanover Isaac E.","owner_display_name":"Ciechanover Isaac E.","owner_url":"/insider/0001612096","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3900.0,"shares_display":"3,900","price_per_share":34.702564102564104,"price_display":"34.70","price_state":"stated","total_value":135340.0,"total_display":"135,340.00","total_whole":"135,340","shares_owned_after":12378.0,"shares_owned_after_display":"12,378","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-12-28","filed_date":"2018-12-28","scope":"insider","n_lines":2},{"id":6002014,"accession":"0001209191-18-064352","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-18-064352","line_url":"/filing/0001209191-18-064352","is_derivative":false,"issuer_cik":"0001604464","issuer_name":"Atara Biotherapeutics, Inc.","issuer_ticker":"ATRA","issuer_name_source":null,"issuer_url":"/issuer/0001604464","owner_cik":"0001612096","owner_name":"Ciechanover Isaac E.","owner_display_name":"Ciechanover Isaac E.","owner_url":"/insider/0001612096","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3900.0,"shares_display":"3,900","price_per_share":33.04938717948718,"price_display":"33.05","price_state":"stated","total_value":128892.61,"total_display":"128,892.61","total_whole":"128,893","shares_owned_after":16431.0,"shares_owned_after_display":"16,431","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-12-27","filed_date":"2018-12-28","scope":"insider","n_lines":2},{"id":6914338,"accession":"0001209191-18-062527","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-18-062527","line_url":"/filing/0001209191-18-062527#line-2","is_derivative":false,"issuer_cik":"0001604464","issuer_name":"Atara Biotherapeutics, Inc.","issuer_ticker":"ATRA","issuer_name_source":null,"issuer_url":"/issuer/0001604464","owner_cik":"0001612096","owner_name":"Ciechanover Isaac E.","owner_display_name":"Ciechanover Isaac E.","owner_url":"/insider/0001612096","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3900.0,"shares_display":"3,900","price_per_share":42.75,"price_display":"42.75","price_state":"stated","total_value":166725.0,"total_display":"166,725.00","total_whole":"166,725","shares_owned_after":19678.0,"shares_owned_after_display":"19,678","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-12-13","filed_date":"2018-12-13","scope":"insider"},{"id":6914333,"accession":"0001209191-18-062527","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-18-062527","line_url":"/filing/0001209191-18-062527#line-1","is_derivative":false,"issuer_cik":"0001604464","issuer_name":"Atara Biotherapeutics, Inc.","issuer_ticker":"ATRA","issuer_name_source":null,"issuer_url":"/issuer/0001604464","owner_cik":"0001612096","owner_name":"Ciechanover Isaac E.","owner_display_name":"Ciechanover Isaac E.","owner_url":"/insider/0001612096","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3900.0,"shares_display":"3,900","price_per_share":42.56,"price_display":"42.56","price_state":"stated","total_value":165984.0,"total_display":"165,984.00","total_whole":"165,984","shares_owned_after":23578.0,"shares_owned_after_display":"23,578","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-12-12","filed_date":"2018-12-13","scope":"insider"},{"id":6370788,"accession":"0001209191-18-060311","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-18-060311","line_url":"/filing/0001209191-18-060311","is_derivative":false,"issuer_cik":"0001604464","issuer_name":"Atara Biotherapeutics, Inc.","issuer_ticker":"ATRA","issuer_name_source":null,"issuer_url":"/issuer/0001604464","owner_cik":"0001612096","owner_name":"Ciechanover Isaac E.","owner_display_name":"Ciechanover Isaac E.","owner_url":"/insider/0001612096","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3900.0,"shares_display":"3,900","price_per_share":41.85435897435897,"price_display":"41.85","price_state":"stated","total_value":163232.0,"total_display":"163,232.00","total_whole":"163,232","shares_owned_after":27478.0,"shares_owned_after_display":"27,478","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-11-29","filed_date":"2018-11-29","scope":"insider","n_lines":2},{"id":6370777,"accession":"0001209191-18-060311","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-18-060311","line_url":"/filing/0001209191-18-060311","is_derivative":false,"issuer_cik":"0001604464","issuer_name":"Atara Biotherapeutics, Inc.","issuer_ticker":"ATRA","issuer_name_source":null,"issuer_url":"/issuer/0001604464","owner_cik":"0001612096","owner_name":"Ciechanover Isaac E.","owner_display_name":"Ciechanover Isaac E.","owner_url":"/insider/0001612096","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3900.0,"shares_display":"3,900","price_per_share":38.923846153846156,"price_display":"38.92","price_state":"stated","total_value":151803.0,"total_display":"151,803.00","total_whole":"151,803","shares_owned_after":32578.0,"shares_owned_after_display":"32,578","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-11-28","filed_date":"2018-11-29","scope":"insider","n_lines":2},{"id":6479660,"accession":"0001209191-18-058820","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-18-058820","line_url":"/filing/0001209191-18-058820","is_derivative":false,"issuer_cik":"0001604464","issuer_name":"Atara Biotherapeutics, Inc.","issuer_ticker":"ATRA","issuer_name_source":null,"issuer_url":"/issuer/0001604464","owner_cik":"0001612096","owner_name":"Ciechanover Isaac E.","owner_display_name":"Ciechanover Isaac E.","owner_url":"/insider/0001612096","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3900.0,"shares_display":"3,900","price_per_share":35.25871794871795,"price_display":"35.26","price_state":"stated","total_value":137509.0,"total_display":"137,509.00","total_whole":"137,509","shares_owned_after":35278.0,"shares_owned_after_display":"35,278","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-11-15","filed_date":"2018-11-15","scope":"insider","n_lines":2},{"id":6479654,"accession":"0001209191-18-058820","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-18-058820","line_url":"/filing/0001209191-18-058820","is_derivative":false,"issuer_cik":"0001604464","issuer_name":"Atara Biotherapeutics, Inc.","issuer_ticker":"ATRA","issuer_name_source":null,"issuer_url":"/issuer/0001604464","owner_cik":"0001612096","owner_name":"Ciechanover Isaac E.","owner_display_name":"Ciechanover Isaac E.","owner_url":"/insider/0001612096","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3900.0,"shares_display":"3,900","price_per_share":33.98538461538462,"price_display":"33.99","price_state":"stated","total_value":132543.0,"total_display":"132,543.00","total_whole":"132,543","shares_owned_after":39778.0,"shares_owned_after_display":"39,778","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-11-14","filed_date":"2018-11-15","scope":"insider","n_lines":2},{"id":6079859,"accession":"0001209191-18-055990","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-18-055990","line_url":"/filing/0001209191-18-055990#line-5","is_derivative":false,"issuer_cik":"0001604464","issuer_name":"Atara Biotherapeutics, Inc.","issuer_ticker":"ATRA","issuer_name_source":null,"issuer_url":"/issuer/0001604464","owner_cik":"0001612096","owner_name":"Ciechanover Isaac E.","owner_display_name":"Ciechanover Isaac E.","owner_url":"/insider/0001612096","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1700.0,"shares_display":"1,700","price_per_share":34.39,"price_display":"34.39","price_state":"stated","total_value":58463.0,"total_display":"58,463.00","total_whole":"58,463","shares_owned_after":43878.0,"shares_owned_after_display":"43,878","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-10-23","filed_date":"2018-10-23","scope":"insider"},{"id":6079858,"accession":"0001209191-18-055990","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-18-055990","line_url":"/filing/0001209191-18-055990#line-4","is_derivative":false,"issuer_cik":"0001604464","issuer_name":"Atara Biotherapeutics, Inc.","issuer_ticker":"ATRA","issuer_name_source":null,"issuer_url":"/issuer/0001604464","owner_cik":"0001612096","owner_name":"Ciechanover Isaac E.","owner_display_name":"Ciechanover Isaac E.","owner_url":"/insider/0001612096","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1400.0,"shares_display":"1,400","price_per_share":33.17,"price_display":"33.17","price_state":"stated","total_value":46438.0,"total_display":"46,438.00","total_whole":"46,438","shares_owned_after":45578.0,"shares_owned_after_display":"45,578","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-10-23","filed_date":"2018-10-23","scope":"insider"}],"collapsed":true,"next_cursor":"2018-10-23|6079858","ledger_fault":false,"count":{"value":327,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":327,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":327},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001604464","name":"Atara Biotherapeutics, Inc.","url":"/issuer/0001604464","role":"Director, Officer (Chief Executive Officer)","n_filings":94,"first_seen":"2015-04-24","last_seen":"2019-05-31"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001612096","retrieved_at":"2026-08-23T10:54:11+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}